In a new policy study from R Street Trade Policy Counsel Clark Packard and Associate Fellow Bill Watson, the authors discuss how at a time when policymakers in both parties are looking to lower drug costs, reshoring the supply chain would be extremely costly for consumers, and would dampen innovation and hurt competitiveness for a global industry.

They find that data is imperfect, but we are not overly reliant on China for finished pharmaceuticals and active pharmaceutical ingredients.

Protectionism Won’t Protect American Access to Pharmaceuticals